Galderma says GLP-1 use is lifting aesthetics growth as sales rise nearly 25%

CEO Flemming Ørnskov said broader use of weight-loss drugs in the U.S. is creating early demand for fillers and collagen stimulators aimed at facial volume loss after significant weight reduction.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.